These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32422144)

  • 1. Perforin and resistance to SARS coronavirus 2.
    Cunningham L; Simmonds P; Kimber I; Basketter DA; McFadden JP
    J Allergy Clin Immunol; 2020 Jul; 146(1):52-53. PubMed ID: 32422144
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 pneumonia: CD8
    Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
    Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
    Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphopenia in COVID-19: Therapeutic opportunities.
    Fathi N; Rezaei N
    Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
    Loscocco GG
    Int J Hematol; 2020 Jul; 112(1):125-126. PubMed ID: 32474804
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
    Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
    J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
    Alunno A; Carubbi F; Rodríguez-Carrio J
    RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 cytokine storm: the interplay between inflammation and coagulation.
    Jose RJ; Manuel A
    Lancet Respir Med; 2020 Jun; 8(6):e46-e47. PubMed ID: 32353251
    [No Abstract]   [Full Text] [Related]  

  • 10. More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells.
    Rijkers G; Vervenne T; van der Pol P
    Cell Mol Immunol; 2020 Jul; 17(7):771-772. PubMed ID: 32467616
    [No Abstract]   [Full Text] [Related]  

  • 11. Natural Killer Cell Dysfunction and Its Role in COVID-19.
    van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.
    Hanley B; Roufosse CA; Osborn M; Naresh KN
    Br J Haematol; 2020 Jun; 189(6):1062-1063. PubMed ID: 32369628
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
    Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
    Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
    Lin Q; Zhu L; Ni Z; Meng H; You L
    J Microbiol Immunol Infect; 2020 Oct; 53(5):821-822. PubMed ID: 32249185
    [No Abstract]   [Full Text] [Related]  

  • 15. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term infection of SARS-CoV-2 changed the body's immune status.
    Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
    Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
    Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
    Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell-Free Therapies: Novel Approaches for COVID-19.
    Maron-Gutierrez T; Rocco PRM
    Front Immunol; 2020; 11():583017. PubMed ID: 33072130
    [No Abstract]   [Full Text] [Related]  

  • 19. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.
    Cunningham L; Kimber I; Basketter DA; McFadden JP
    Autoimmun Rev; 2020 Jul; 19(7):102563. PubMed ID: 32380318
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel Coronavirus SARS-CoV-2 Target and Disable Natural Killer Cells: Core Immune Effectors for Fighting the Disease.
    Jewett A
    Crit Rev Immunol; 2020; 40(2):167-171. PubMed ID: 32749094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.